697 filings
Page 3 of 35
6-K
x8j12a 1l
18 Aug 23
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
7:06am
6-K
t43j9s
7 Aug 23
Report of Foreign Private Issuer
4:15pm
6-K
etejnn414 tr
31 Jul 23
Current report (foreign)
4:15pm
6-K
47xxd9jbr08thh4fa7
17 Jul 23
Report of Foreign Private Issuer
7:11am
6-K
reprh
29 Jun 23
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
7:10am
6-K
mry 90cxe
23 Jun 23
2023 Annual General Meeting of Shareholders
4:15pm
6-K
hp2xtg
13 Jun 23
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
7:08am
6-K
j56hmf6epmd j3ed2
1 Jun 23
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
7:07am
6-K
eo4 2fv4kspe
30 May 23
Report of Foreign Private Issuer
7:14am
6-K
822bvvvdmx
9 May 23
Report of Foreign Private Issuer
7:07am
6-K
ilpeff452nr
2 May 23
Report of Foreign Private Issuer
7:08am
EFFECT
5l4nxozqrub5cbgwpo
25 Apr 23
Notice of effectiveness
12:15am
6-K
njywecx8qe6
24 Apr 23
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
7:09am
POS AM
ghe vjcxzd2vx5lpwof
21 Apr 23
Prospectus update (post-effective amendment)
4:16pm
S-8
xr5f 867tjw
21 Apr 23
Registration of securities for employees
4:15pm
6-K
r86neq8gjdh
10 Apr 23
Report of Foreign Private Issuer
7:06am
POS AM
7sl 7w3xaq8b8sgcntq
31 Mar 23
Prospectus update (post-effective amendment)
4:30pm
6-K
vv453o10p
30 Mar 23
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
7:56am
6-K
cc9tnh3irfxb2te62p
13 Mar 23
Report of Foreign Private Issuer
7:08am